C4 Therapeutics, Inc. (CCCC) - Guggenheim 3rd Annual Healthcare Innovation Conference - C4 THERAPEUTICS INC

Explicit Guidance:

• Clinical Trial Enrollment: Momentum study (late-line myeloma) enrollment expected to be completed in the first quarter of 2027; management states "no reason to change that guidance."
• Investigator-Assessed Data Update: Initial investigator-assessed data for the Momentum study targeted for release in the second half of 2026.
• Combination Study Data: Data from the Simcitamide + L-revatinib (BCMA-targeted) combination study (covering cohorts at 75mcg and escalated to 100mcg) expected mid-year 2027.
• New Study Initiation: Phase 1b trials for a Dara-carfilzomib combination anticipated to begin "next year" (2025).
• Regulatory Strategy: Targeting accelerated approval via the Momentum study (non-randomized) with a data package submission potentially in 2028 or beyond; accelerated approval sought via MRD-negative CR rates (targeting ≥40%) in a future Phase 3 study.

Business-Segment Outlook:

• Therapeutic Positioning: Vision to position Simcitamide as a "backbone therapy" for myeloma by expanding its use from late-line refractory settings into earlier lines of therapy (second-line, potentially first-line) where immune-based strategies are migrating.
• Target Market Shift: Anticipates market evolution where second-line patients with refractory myeloma will be "first and foremost" considered for bite-based or CAR-T regimens; Simcitamide aims to augment these with immune stimulation.
• Commercial Focus: Aiming for a "best-in-class" profile by differentiating via lower doses (75–100mcg) and favorable safety (lowest Grade 4 neutropenia, lowest GCSF use) compared to peers (mezigdomide, iberdomide), allowing for higher exposure and potency.
• Platform Expansion: Strategic pivot of the degrader platform focus from oncology toward inflammation, neuroinflammation, and neurodegeneration to leverage unique target mechanisms.

Market and Competitive Outlook:

• Competitive Differentiation: Unique position as the only company currently pursuing an IMiD-bite combination in a regulatory study (others limited to Phase 1 or non-regulatory); differentiated from mezigdomide/iberdomide which required dose reductions (0.6/0.3) in similar combinations, whereas Simcitamide cleared 75mcg and escalated to 100mcg.
• Efficacy Bar: Targeting ≥40% overall response rate (current data shows 36–53%) to exceed the assumed background off-label response rate of 25% and provide a signal beyond contemporary peers.
• Market Evolution: Believes the field has evolved to match internal predictions (ASCO guideline changes), validating the strategy to bring immune-directed agents earlier in the treatment algorithm.

Macro / Industry Outlook:

• Treat-to-Target Trend: Industry-wide shift observed where highly effective drugs (CAR-T, BITEs) are migrating from late-line to second-line and potentially first-line settings, creating a need for potent, well-tolerated backbone agents in earlier stages.
• Trial Design Trends: Accelerated approval pathways increasingly relying on MRD-negative Complete Response (CR) rates as a surrogate for long-term durability, a metric the company is prioritizing in upcoming Phase 3 design.

Strategic Initiatives:

• Clinical Expansion: Expanded operational footprint for the Momentum trial from 13 centers (US-only) to 60 sites across the US, UK, and Western Europe to broaden patient accessibility and prescriber diversity.
• Partnership Strategy: Continuing to seek non-equity dilutive capital through collaborations for the expanded platform (neuro/immune targets); evaluating partnering opportunities for Simcitamide itself only if they offer value addition beyond internal capabilities.
• Combination Pipeline: Launching new Phase 1b studies to establish Simcitamide as a predictable, safe combination partner with novel agents (e.g., Dara-carfilzomib) and validating doses for combinations with BCMA-targeted antibodies.
• Platform Leverage: Utilizing the platform to generate clinical proof of concept in non-oncology sectors (neuro/inflammation) to attract capital and expand the pipeline.

Risks and Headwinds to Outlook:

• Regulatory Scrutiny: Accelerated approval depends on safety data (lack of dose modifications/interruptions) alongside efficacy; the agency requires independent response criteria and safety/duration data, not just investigator assessment.
• Market Competition: Must prove superiority against established CAR-T and BITE therapies in earlier lines; success dependent on demonstrating higher quality responses (MRD-negative CR) and durability.
• Dose Sensitivity: While the model suggests weak correlation between neutropenia and higher exposure, the efficacy bar for accelerated approval remains high and must be met within the context of evolving contemporaneous peer outcomes.

Management Tone on the Future:

• High Confidence: Describes Simcitamide's profile as "most robust de-risk proof-of-concept" with the "best of both worlds" (efficacy of mezigdomide, safety of iberdomide).
• Validation of Strategy: Expresses reassurance that external market trends (ASCO guidelines, competitor data) are aligning perfectly with their pre-existing development plan.
• Differentiation Confidence: Emphasizes "stark differentiating fact" in combination tolerability compared to peers, citing ability to maintain 75–100mcg doses versus competitor dose reductions.

Miscellaneous:

• Trial Design Nuance: Acknowledges that investigator-assessed response will likely mirror independent response but stresses that FDA approval will rely strictly on independent criteria combined with safety.
• Patient Demographics: Noting that refractory myeloma is a disease of older persons, the company emphasizes the need for simple-to-give all-oral regimens for the broader community patient base, not just academic centers.